LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER

1 . A compound of Formula (Ia) or (Ib):

with:

n:

0,1

m:

1,2,3,4

Z:

—CO 2 H, —SO 2 H, —SO 3 H, —SO 4 H, —PO 2 H, —PO 3 H,

—PO 4 H 2

X:

Naphthyl, Phenyl, Biphenyl, Indolyl (=2,3-benzopyrrolyl),

Benzothiazolyl

Y:

Aryl, Alkylaryl, Cyclopentyl, Cyclohexyl, Cycloheptyl

Che-

1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid

lator:

(=DOTA),

N,N″-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-

N,N″-diacetic acid (=HBED-CC),

1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA),

2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid

(NODAGA),

2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-

yl)pentanedioic acid

(DOTAGA),

1,4,7-triazacyclononane phosphinic acid (TRAP),

1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic

acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO),

3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-

triacetic acid (=PCTA),

N′-{5-[Acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-

aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-

hydroxysuccinamide (DFO),

Diethylenetriaminepentaacetic acid (DTPA)

Trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA)

1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A)

p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA)

1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M)

2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B)

1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA)

2 . The compound of claim 1 having the structure R′-Linker-R with R′=DOTA and R=. Glu-Urea-Lys:

wherein the linker is selected from:

3 . The compound of claim 1 , selected from the following:

4 . A radiolabeled compound comprising the compound of claim 1 .

5 . A metal complex comprising a radionuclide and a compound of claim 1 .

6 . The metal complex of claim 5 , wherein the radionuclide is 111 In, 90 Y, 68 Ga, 177 Lu, 99m Tc, 64 Cu, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac or Fe.

7 . A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier.

8 . The compound of claim 1 for use in a method of imaging in a patient.

9 . The compound of claim 1 for use in a method of diagnosing prostate cancer and/or metastasis thereof.

10 . The compound of claim 1 for use in a method of treating prostate cancer and/or metastasis thereof.

11 . A pharmaceutical composition comprising the metal complex of claim 5 , or a pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier.

12 . The metal complex of claim 5 for use in a method of imaging in a patient.

13 . The metal complex of claim 5 for use in a method of diagnosing prostate cancer and/or metastasis thereof.

14 . The metal complex of claim 5 for use in a method of treating prostate cancer and/or metastasis thereof.